Overview

EMANATE: Phase 3 Study of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Genetic Variants

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The protocol describes a randomized, double-blind, placebo-controlled trial with 5 independent sub-studies of setmelanotide in patients with obesity and at least one of 6 specific gene defects in the Melanocortin-4 Receptor pathway: - POMC or PCSK1 (Sub-study 035a) - LEPR (Sub-study 035b) - SRC1 (Sub-study 035c) - SH2B1 (Sub-study 035d) - PCSK1 N221D (Sub-study 035e) These 5 sub-studies have high degree of similarities. The objectives and endpoints are identical for all 5 sub-studies.
Phase:
Phase 3
Details
Lead Sponsor:
Rhythm Pharmaceuticals, Inc.